Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05846737 | BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT | Phase 2 | withdrawn | May 6, 2023 | Institute of Hematology & Blood Diseases Hospital, China | The study was withdrawn due to the inability to enroll participants. | Enrollment / accrual |
| NCT06769555 | BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic… | N/A | withdrawn | Jan 10, 2025 | Institute of Hematology & Blood Diseases Hospital, China | The study protocol was withdrawn because, after modifications, the study transitioned from an… | Investigator |
| NCT07282548 | Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least… | — | withdrawn | Dec 15, 2025 | Ipsen | Withdrawn prior to enrolment after review of updated safety data | Safety / toxicity |
| NCT06125028 | [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma(LYMFOR) | Phase 3 | terminated | Nov 9, 2023 | Pentixapharm AG | low recruitment rate | Enrollment / accrual |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell… | Phase 2 | terminated | Aug 9, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer… | Phase 2 | terminated | Oct 25, 2021 | Pfizer | A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2… | Safety / toxicity |
| NCT06163898 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With… | Phase 1 | terminated | Dec 11, 2023 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | terminated | Aug 11, 2022 | UNC Lineberger Comprehensive Cancer Center | Funding | Funding |
| NCT01081028 | Connect® MM- The Multiple Myeloma Disease Registry | — | terminated | Mar 5, 2010 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High…(CPIT001) | Phase 1 / Phase 2 | terminated | Feb 12, 2016 | Hackensack Meridian Health | Lack of Accrual | Enrollment / accrual |
| NCT05618366 | Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 | terminated | Nov 16, 2022 | Weill Medical College of Cornell University | Low accrual | Enrollment / accrual |
| NCT07049432 | N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory…(CARMEN-803) | Phase 1 | withdrawn | Jul 3, 2025 | University of Utah | Drug Unavailable | Other (stated, no rule matched) |
| NCT01453088 | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With… | Phase 2 | terminated | Oct 17, 2011 | Hackensack Meridian Health | Lack of Accrual | Enrollment / accrual |
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in… | Phase 3 | withdrawn | Mar 15, 2024 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Replaced with another clinical trial. | Other (stated, no rule matched) |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell… | Phase 1 | terminated | Jun 6, 2018 | MEI Pharma, Inc. | Business reasons, not related to safety or efficacy results. | Safety / toxicity |
| NCT06068400 | Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed… | N/A | terminated | Oct 5, 2023 | Guangzhou Bio-gene Technology Co., Ltd | Due to corporate strategic adjustment. | Sponsor / business decision |
| NCT04676360 | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | Phase 2 | terminated | Dec 21, 2020 | Jacob Soumerai, MD | The study was closed given lack of efficacy and plans to publish this negative study. | Efficacy / futility |
| NCT04827563 | Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib | — | terminated | Apr 1, 2021 | University of Chicago | Study terminated by PI | Other (stated, no rule matched) |
| NCT03919175 | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and… | Phase 2 | terminated | Apr 18, 2019 | Massachusetts General Hospital | Umbralisib development terminated; closed to accrual 8/29/2022 | Enrollment / accrual |
| NCT04205838 | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy… | Phase 2 | terminated | Dec 20, 2019 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT04268277 | Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY | Phase 2 | terminated | Feb 13, 2020 | University of Ulm | Due to slow recruitment caused by the COVID-19 pandemic and associated retrictions and the… | COVID-19 / pandemic |
| NCT03990961 | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | terminated | Jun 19, 2019 | University of Chicago | Study was closed early due to slow enrollment. | Enrollment / accrual |
| NCT03031730 | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple… | Phase 1 | terminated | Jan 26, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With… | Phase 1 / Phase 2 | terminated | Dec 15, 2017 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04285268 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Feb 26, 2020 | Rutgers, The State University of New Jersey | This study was never submitted to the IRB for review and approval. No research subjects were… | Enrollment / accrual |
| NCT05590377 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory…(iinnovate-3) | Phase 1 / Phase 2 | terminated | Oct 21, 2022 | Teva Branded Pharmaceutical Products R&D LLC | After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with… | Enrollment / accrual |
| NCT06068881 | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With…(Mandolin) | Phase 2 | withdrawn | Oct 5, 2023 | Epizyme, Inc. | Never started | Other (stated, no rule matched) |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | Phase 1 / Phase 2 | terminated | Jul 12, 2017 | Teva Branded Pharmaceutical Products R&D LLC | Terminated by the sponsor for strategic reasons | Sponsor / business decision |
| NCT05556616 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma(iinnovate-2) | Phase 1 | terminated | Sep 27, 2022 | Teva Branded Pharmaceutical Products R&D LLC | Due to strategic reasons (no safety concerns). | Safety / toxicity |
| NCT06575686 | Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa… | Phase 2 | suspended | Aug 28, 2024 | City of Hope Medical Center | Pending Interim Analysis | Efficacy / futility |
| NCT04716153 | Impact of a Sensory Rehabilitation Program on Olfactory-gustatory Alterations in Patients…(RE-NEZ-SENS) | N/A | terminated | Jan 20, 2021 | University Hospital, Montpellier | Enrolement difficulties | Enrollment / accrual |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | Phase 1 / Phase 2 | suspended | Apr 22, 2021 | Masonic Cancer Center, University of Minnesota | Accrual met | Enrollment / accrual |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | Phase 2 | terminated | Dec 29, 2021 | Novartis Pharmaceuticals | The study was terminated since the sponsor made the decision to discontinue further development of… | Other (stated, no rule matched) |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With… | Phase 1 / Phase 2 | withdrawn | Jul 17, 2025 | UNC Lineberger Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT05675319 | Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for…(AlloRelapseMM) | Phase 3 | terminated | Jan 9, 2023 | Universitätsklinikum Hamburg-Eppendorf | The reason for the end of recruitment is that the recruitment target could not be achieved despite… | Enrollment / accrual |
| NCT04230304 | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | terminated | Jan 18, 2020 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT06106841 | TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | terminated | Oct 30, 2023 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Study terminated for strategic business reasons | Sponsor / business decision |
| NCT04123418 | A Study of WVT078 in Patients With Multiple Myeloma (MM) | Phase 1 | terminated | Oct 10, 2019 | Novartis Pharmaceuticals | The decision was made for business reasons and was not based on any safety or tolerability concerns | Safety / toxicity |
| NCT05179603 | A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Jan 5, 2022 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy…(CARTIFAN-1) | Phase 2 | terminated | Nov 29, 2018 | Nanjing Legend Biotech Co. | The study was terminated early due to a strategic realignment of the sponsor's business plan, not… | Safety / toxicity |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic… | Phase 1 / Phase 2 | terminated | Apr 8, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT01794572 | Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st…(TOMMY) | N/A | terminated | Feb 20, 2013 | Institut Cancerologie de l'Ouest | Low patient recruitement rate and modification of the therapeutic standard | Enrollment / accrual |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired…(DREAMM 13) | Phase 1 | withdrawn | May 21, 2020 | GlaxoSmithKline | Sponsor Decision | Sponsor / business decision |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma(DC15-MM-01) | Phase 1 | terminated | Mar 12, 2024 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated | Enrollment / accrual |
| NCT03498612 | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Phase 2 | terminated | Apr 13, 2018 | University of Washington | Closed per SRC Low Accrual Policy. | Enrollment / accrual |
| NCT05065047 | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell… | Phase 1 | terminated | Oct 1, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive…(UPCC 25406) | Phase 1 / Phase 2 | terminated | Oct 21, 2008 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | Incyte Corporation | This decision follows recruitment difficulties. No safety-related concerns impacted this decision. | Safety / toxicity |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic…(LIMBER) | Phase 1 / Phase 2 | terminated | Oct 9, 2020 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in… | Phase 2 | terminated | Jul 18, 2018 | University of California, San Diego | The trial met its primary endpoint. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 29, 2026source: clinicaltrials